

This month's Market Minute reflects the views of Clearstead's Research Team and was composed by [Joseph D. Boushelle, CFA, CAIA, Senior Managing Director, Research](#).



OVERVIEW

Global equity markets bounced back strongly in April from the selloff in March as U.S. equities had their strongest monthly performance since 1987¹. Investors were able to shake off dismal economic numbers as first quarter GDP growth came in at -4.8%, over 30 million people filed unemployment claims in the U.S. over the last 6 weeks, U.S. consumer spending slumped 7.3%, the most ever, and oil traded in negative territory for the first time ever¹. Despite these negative headlines, markets looked to the future and saw glimmers of hope in continued global government stimulus measures, potential coronavirus treatments, a “flattening of the curve,” and loosening of quarantine restrictions globally. While we do expect to see rosier days, the road ahead is likely to be a bumpy one.

DOMESTIC EQUITY

As of April 30, 2020

| U.S. EQUITY MARKETS | | | | |
|---------------------|---------|-----------------|--------------|--------|
| Index | 1 Month | Quarter-To-Date | Year-To-Date | 1 Year |
| DJIA | 11.2% | 11.2% | -14.1% | -6.2% |
| S&P 500 | 12.8% | 12.8% | -9.3% | 0.9% |
| Russell 2000 | 13.7% | 13.7% | -21.1% | -16.4% |
| Russell 1000 Growth | 14.8% | 14.8% | -1.4% | 10.8% |
| Russell 1000 Value | 11.2% | 11.2% | -18.5% | -11.0% |

U.S. equity markets rebounded in April as concerns about the coronavirus and its potentially negative economic impact subsided during the month. The S&P 500 rallied up 12.8%; its third best month since World War II¹. Despite trailing large caps (S&P 500) earlier in the month, small caps (Russell 2000) are outperforming large caps for the month by about 0.9%.

Especially given the strong performance in the equity markets, we still find it prudent to be defensive in our position given the volatility of sentiment regarding the coronavirus and the lack of clarity around the virus's impact on corporate earnings and economic growth.

INTERNATIONAL EQUITY

As of April 30, 2020

| INTERNATIONAL EQUITY MARKETS | | | | |
|------------------------------|---------|-----------------|--------------|--------|
| Index | 1 Month | Quarter-To-Date | Year-To-Date | 1 Year |
| MSCI ACWI ex USA | 7.6% | 7.6% | -17.5% | -11.5% |
| MSCI EAFE | 6.5% | 6.5% | -17.8% | -11.3% |
| MSCI Emerging Markets | 9.2% | 9.2% | -16.6% | -12.0% |
| MSCI EAFE Small Cap | 10.4% | 10.4% | -20.0% | -12.3% |

Non-U.S. equity markets also rebounded in April around the potential of reopening markets, but significantly lagged the gains made in the U.S. markets. The developed markets (MSCI EAFE) were up 6.5% and the emerging markets (MSCI EM) were up 9.2%. Small cap stocks (MSCI EAFE Small Cap) led the rally in both EM and developed markets, gaining as much as 4 percentage-points more than their large cap peers. The U.S. dollar grinded higher against many Emerging Market currencies as well as several key developed market currencies (i.e. Euro, Canadian dollar).

Chinese equity markets rose in line with other EM markets in April, but YTD have outperformed the US market on a relative basis and is only down about -5.0%¹. The Chinese economy continues to normalize after it lifted quarantines in most places in late March/early April. By mid-April, most Chinese businesses have reopened, and its manufacturers had the ability to resume nearly full production. However, demand for many Chinese exports—excepting medical supplies and products—is weak as many of their US and European customers have cancelled or delayed delivery on many products due to ongoing shutdowns in their home markets. Nonetheless, the earnings outlook for most domestically-oriented Chinese firms looks to be flat to mildly positive for 2020 in contrast to most other markets, and the Chinese government—similar to efforts in the US and Europe—has implanted a series of fiscal and monetary measures to support the economy and stabilize its equity markets.

FIXED INCOME

As of March 31, 2020

| FIXED INCOME MARKETS | | | | |
|--------------------------|---------|-----------------|--------------|--------|
| Index | 1 Month | Quarter-To-Date | Year-To-Date | 1 Year |
| BarCap US Aggregate | 1.8% | 1.8% | 5.0% | 10.8% |
| BarCap Global Aggregate | 2.0% | 2.0% | 1.6% | 6.6% |
| BarCap US High Yield | 4.5% | 4.5% | -8.8% | -4.1% |
| JPM Emerging Market Bond | 2.2% | 2.2% | -9.8% | -3.3% |
| BarCap Muni | -1.3% | -1.3% | -1.9% | 2.2% |

Following the March upheaval, as the month progressed, April activity calmed down and investors began to look for bargains. During March 10-year US Treasury bond yields traded in range from a low of 0.31% to a high of 1.27%¹. April's trading range has been much tighter from 0.54% to 0.78% and is closing the month at 0.64%¹. This same behavior could be found in other fixed income sectors such as investment grade and high yield corporate securities that saw spreads not only tighten but also trade in a less volatile environment.

Key to outperformance was to be invested where the Federal Reserve said they were buying. The Fed stepped in with a broad array of actions to limit the economic damage from the pandemic, including lending to support households, employers, financial markets, and state and local governments. For example, under the new Secondary Market Corporate Credit Facility (SMCCF), the Fed may purchase existing corporate bonds as well as exchange-traded funds investing in investment-grade corporate bonds. The markets responded favorably to this action as the Bloomberg Barclays Investment Grade Corporate Index returned 5.24% for the month versus 0.64% for the US Treasury Index¹. Until there is clearer economic visibility, the Fed's financial market support should help stabilize markets and reduce volatility.

CLOSING

Bear market rallies are not uncommon during a recession. While we do not have a crystal ball view into the future, the S&P 500 is trading at levels seen in early October 2019 and valuations look stretched as earnings estimates continue to come down.

The probability of the most severe scenarios continues to come down as we learn more about the coronavirus and dozens of pharmaceutical and biotech firms work on potential treatments and vaccines, but we still expect the impact of the virus to continue to be felt as people maintain their “social distance” and companies work through excessive balance sheet leverage. Given this backdrop, we could see the market retest March lows in the coming weeks or months before the nature of post-COVID 19 recovery becomes clearer and visibility into the corporate earnings outlook is sufficient to support further advances in financial markets. This could create great buying opportunities for patient investors.

Sources:

Index performance data in tables provided by Morningstar, as of 4/30/2020.

1 Bloomberg

Disclosures

Information provided in this article is general in nature, is provided for informational purposes only, and should not be construed as investment advice. The views expressed by the author are based upon the data available at the time the article was written. Any such views are subject to change at any time based on market or other conditions. Clearstead disclaims any liability for any direct or incidental loss incurred by applying any of the information in this article. All investment decisions must be evaluated as to whether it is consistent with your investment objectives, risk tolerance, and financial situation. The performance data shown represent past performance. Past performance is not indicative of future results. Current performance data may be lower or higher than the performance data presented.